Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC Post published:August 24, 2023 Continue ReadingAlentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY Post published:April 26, 2023 Continue ReadingALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY
ALENTIS TO PRESENT DATA AT AACR Post published:April 14, 2023 Continue ReadingALENTIS TO PRESENT DATA AT AACR
ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1 Post published:April 13, 2023 Continue ReadingALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1
ALENTIS THERAPEUTICS makes key leadership appointments Post published:February 17, 2023 Continue ReadingALENTIS THERAPEUTICS makes key leadership appointments
Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1 Post published:January 9, 2023 Continue ReadingPositive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer Post published:January 5, 2023 Continue ReadingAlentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer
Preclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs Post published:December 21, 2022 Continue ReadingPreclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs
Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model Post published:December 1, 2022 Continue ReadingAlentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model
